Ensoma has received rare pediatric disease and orphan drug designations from the FDA for EN-374 for the treatment of X-CGD.

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

Torrey Pines Investment, a specialty life-science investment company based in San Diego, CA, and Oost NL, a regional development agency supporting innovation-driven companies, announced the pre-seed ...

A new study released by Geotab Inc. ("Geotab"), a global leader in connected transportation solutions, demonstrates a need ...